{"DataElement":{"publicId":"7263433","version":"1","preferredName":"Tumor Mass H&E Staining Not Done Checkbox Indicator","preferredDefinition":"A checkbox indicator to designate that Hematoxylin and Eosin (H&E) staining was not performed.","longName":"7263296v1.0:2185839v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7263296","version":"1","preferredName":"Tumor Mass Hematoxylin and Eosin Staining Not Done","preferredDefinition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells._Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen._Indicates a task, process or examination that has either not been initiated or not been completed.","longName":"4976411v1.0:7263294v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"4976411","version":"1","preferredName":"Tumor Mass","preferredDefinition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells.","longName":"C98275","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Mass","conceptCode":"C98275","definition":"A benign or malignant pathologic structure in any part of the body, resulting from a neoplastic accumulation of cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1DC5FA96-6845-8A34-E050-BB89AD4344BC","latestVersionIndicator":"Yes","beginDate":"2015-08-20","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-08-20","modifiedBy":"ONEDATA","dateModified":"2015-08-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7263294","version":"1","preferredName":"Hematoxylin and Eosin Staining Method Not Done","preferredDefinition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.:Indicates a task, process or examination that has either not been initiated or not been completed.","longName":"C23011:C49484","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematoxylin and Eosin Staining Method","conceptCode":"C23011","definition":"Hematoxylin-and-eosin, or H&E, is a routine staining procedure of tissue sections. This staining method uses two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A44B6560-CD89-4386-E053-F662850A744A","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-27","modifiedBy":"ONEDATA","dateModified":"2020-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A44B6560-CD9A-4386-E053-F662850A744A","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-27","modifiedBy":"KNABLEJ","dateModified":"2020-04-28","changeDescription":"4/28/20 jk Released per SME review and approval.  4/27/20 jk created for CPTAC THCA Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2185839","version":"1","preferredName":"Checkbox Indicator","preferredDefinition":"Indicator determining determining whether or not certain stated circumstances exist._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"CHECKBOX_IND","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2183782","version":"1","preferredName":"NCIP","preferredDefinition":"Cancer Biomedical Informatics Grid","longName":"NCIP","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB2549-3BE3-73F7-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-05-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DECA4562-CD55-17B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-07-09","modifiedBy":"HARTLEYG","dateModified":"2014-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634324","version":"1","longName":"CM Baseline","context":"OCCPR"},{"publicId":"6601282","version":"1","longName":"Esophagus","context":"OCCPR"},{"publicId":"6779553","version":"1","longName":"ESCA Baseline","context":"OCCPR"},{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779538","version":"1","longName":"CHOL Baseline","context":"OCCPR"},{"publicId":"6779541","version":"1","longName":"LIHC Baseline","context":"OCCPR"},{"publicId":"6776735","version":"1","longName":"Eye","context":"OCCPR"},{"publicId":"6779574","version":"1","longName":"UVM Baseline","context":"OCCPR"},{"publicId":"10000439","version":"1","longName":"Thyroid","context":"OCCPR"},{"publicId":"6779571","version":"1","longName":"THCA Baseline","context":"OCCPR"},{"publicId":"6570063","version":"1","longName":"Cervix","context":"OCCPR"},{"publicId":"6779609","version":"1","longName":"CESC Baseline","context":"OCCPR"},{"publicId":"5635361","version":"1","longName":"Bladder","context":"OCCPR"},{"publicId":"6779606","version":"1","longName":"BLCA Baseline","context":"OCCPR"},{"publicId":"7634285","version":"1","longName":"HNSCC Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"H&E staining not done","type":"Preferred Question Text","description":"H&E staining not done","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A44AE26E-A5A2-4EB2-E053-F662850ACCF1","latestVersionIndicator":"Yes","beginDate":"2020-04-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-04-27","modifiedBy":"COLBERTM","dateModified":"2022-08-18","changeDescription":"7/27/21 jk added Phase 3 CM Baseline CSI.  7/22/20 jk added BLCA CSI.  7/1/20 jk added CESC CSI. 6/23/20 jk added LIHC and CHOL CSIs. 6/14/20 jk added CPTAC ESCA Baseline CSI.   5/13/20 jk added for UVM pending SME approval. 4/28/20 jk Released per SME review and approval.  4/27/20 jk created for CPTAC THCA Baseline CRF.","administrativeNotes":"8/18/22 Added HSNCC Baseline CSI per jk. and spreadsheet. MR;","unresolvedIssues":null,"deletedIndicator":"No"}}